NASDAQ:XERS Xeris Biopharma (XERS) Stock Price, News & Analysis $17.09 +0.29 (+1.73%) As of 12:27 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Xeris Biopharma Stock (NASDAQ:XERS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Xeris Biopharma alerts:Sign Up Key Stats Today's Range$16.75▼$17.2850-Day Range$7.45▼$16.8052-Week Range$5.25▼$17.28Volume1.05 million shsAverage Volume2.15 million shsMarket Capitalization$3.12 billionP/E RatioN/ADividend YieldN/APrice Target$17.00Consensus RatingModerate Buy Company Overview Xeris Biopharma is a commercial-stage biopharmaceutical company focused on developing and providing treatments for people with endocrine and other serious health conditions. Its products include Gvoke, a ready-to-use glucagon product for the treatment of severe hypoglycemia, and Recorlev, a treatment for adults with endogenous hypercortisolemia associated with Cushing syndrome when surgery is not an option or has not been curative. The company also develops drug-delivery technologies intended to make medicines easier to store and administer. Its formulation platforms support products designed for injection, including ready-to-use and room-temperature-stable formulations. Xeris was formerly known as Xeris Pharmaceuticals and became Xeris Biopharma Holdings following its 2021 combination with Strongbridge Biopharma. The company is based in Chicago and markets its products in the United States.AI Generated. May Contain Errors. Read More Xeris Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks42nd Percentile Overall ScoreXERS MarketRank™: 2.07883872686 of 5 starsXeris Biopharma scored higher than 42% of companies evaluated by MarketBeat, and ranked 661st out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.3 / 5Analyst RatingModerate Buy Consensus RatingXeris Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.Upside/DownsideThe consensus price target for Xeris Biopharma is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageXeris Biopharma has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Xeris Biopharma's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth93.33% Earnings GrowthEarnings for Xeris Biopharma are expected to grow by 93.33% in the coming year, from $0.15 to $0.29 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xeris Biopharma is -338.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xeris Biopharma is -338.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXeris Biopharma has a P/B Ratio of 62.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.14% of the float of Xeris Biopharma has been sold short.Short Interest Ratio / Days to CoverXeris Biopharma has a short interest ratio ("days to cover") of 4.34.Change versus previous monthShort interest in Xeris Biopharma has recently increased by 11.95%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldXeris Biopharma does not currently pay a dividend.Dividend GrowthXeris Biopharma does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.69 News SentimentXeris Biopharma has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Xeris Biopharma this week, compared to 4 articles on an average week.Search Interest30 people have searched for XERS on MarketBeat in the last 30 days. This is an increase of 900% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Xeris Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Xeris Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,678,971.00 in company stock.Percentage Held by Insiders4.35% of the stock of Xeris Biopharma is held by insiders.Percentage Held by Institutions42.75% of the stock of Xeris Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Xeris Biopharma's insider trading history. Receive XERS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xeris Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XERS Stock News HeadlinesXeris Biopharma Holdings (XERS) Stock May Be Worth More Following Raised Revenue GuidanceNovember 17 at 11:21 PM | finance.yahoo.comXeris Biopharma (NASDAQ:XERS) Reaches New 52-Week High After Analyst UpgradeNovember 13, 2026 | americanbankingnews.comYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which stock, what price, and when to exit. The list reads the same whether you've traded for twenty years or twenty days, and it doesn't depend on account size. If it's not for you, refund the $7 and still keep the scanner for the full year. One payment, no re-bills.November 18 at 1:00 AM | Profits Run (Ad)Xeris Biopharma: Time For A PauseNovember 12, 2026 | seekingalpha.comAnalysts Issue Forecasts for Xeris Biopharma FY2026 EarningsNovember 12, 2026 | americanbankingnews.comXERS, CARL stocks hit all-time highs today – here’s what analysts are sayingNovember 11, 2026 | msn.comXeris Biopharma (NASDAQ:XERS) Stock: Insider Kevin Mcculloch Sells 25,000 SharesNovember 7, 2026 | insidertrades.comXeris Biopharma (NASDAQ:XERS) Insider Steven Pieper Sells 5,000 Shares of StockNovember 5, 2026 | insidertrades.comSee More Headlines XERS Stock Analysis - Frequently Asked Questions How have XERS shares performed this year? Xeris Biopharma's stock was trading at $7.85 at the beginning of 2026. Since then, XERS shares have increased by 115.8% and is now trading at $16.9370. How were Xeris Biopharma's earnings last quarter? Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) posted its quarterly earnings data on Thursday, November, 5th. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.03. The business earned $107.23 million during the quarter, compared to the consensus estimate of $101.68 million. Xeris Biopharma had a negative net margin of 1.76% and a positive trailing twelve-month return on equity of 147.75%. Read the conference call transcript. When did Xeris Biopharma IPO? Xeris Biopharma (XERS) raised $75 million in an initial public offering on Thursday, June 21st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets served as the underwriters for the IPO and Mizuho Securities was co-manager. Who are Xeris Biopharma's major shareholders? Xeris Biopharma's top institutional shareholders include State Street Corp (3.05%), Goldman Sachs Group Inc. (0.91%), First Trust Advisors LP (0.77%) and Vilga Financial Planning LLC (0.58%). Insiders that own company stock include John Patrick Shannon Jr, Kevin Mcculloch, Steven Pieper, Beth Hecht, John Johnson, Jeffrey W Sherman, Marla Persky, Barbara-Jean A Bormann-Kennedy, Dawn Halkuff and James Aloysius Brady. View institutional ownership trends. How do I buy shares of Xeris Biopharma? Shares of XERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Xeris Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Xeris Biopharma investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Pfizer (PFE), Sorrento Therapeutics (SRNE), NIO (NIO) and Palantir Technologies (PLTR). Company Calendar Last Earnings11/05/2026Today11/18/202638th Annual Healthcare Conference12/01/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 XERS's financial health is in the Green zone, according to TradeSmith. XERS has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:XERS CIK1867096 Webwww.xerispharma.com Phone(844) 445-5704FaxN/AEmployees435Year FoundedN/APrice Target and Rating Average Price Target for Xeris Biopharma$17.00 High Price Target$21.00 Low Price Target$12.00 Potential Upside/Downside-0.1%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.05) Trailing P/E RatioN/A Forward P/E Ratio58.68 P/E GrowthN/ANet Income$550 thousand Net Margins-1.76% Pretax Margin-1.76% Return on Equity147.75% Return on Assets6.03% Debt Debt-to-Equity Ratio3.89 Current Ratio2.15 Quick Ratio1.58 Sales & Book Value Annual Sales$291.85 million Price / Sales10.65 Cash Flow$0.10 per share Price / Cash Flow166.72 Book Value$0.27 per share Price / Book63.03Miscellaneous Outstanding Shares182,700,000Free Float174,753,000Market Cap$3.11 billion OptionableOptionable Beta0.61 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:XERS) was last updated on 11/18/2026 by MarketBeat.com Staff. From Our PartnersGold Trades Near Record Highs: What It Means for MinersBarrick Mining has spent decades building one of the world's great gold districts in Nevada, anchored by Fourm...Wall Street Logic | SponsoredYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,00...Concord Gold Capital | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredWorse than socialismDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same ec...Porter & Company | SponsoredEarn $4,500 a month? Your income may count for moreEarn $4,500 or more a month? Pennie lets you explore personal loan options that consider your income, not just...Pennie Financial | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xeris Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xeris Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.